Navigation Links
Par Pharmaceutical Reports Fourth Quarter and Full Year 2007 Results
Date:2/29/2008

WOODCLIFF LAKE, N.J., Feb. 29 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported fourth quarter and full year 2007 results ended December 31, 2007.

Fourth Quarter and 2007 Results

For the fourth quarter ended December 31, 2007, Par reported total revenues of $155.1 million and income from continuing operations of $5.5 million, or $0.16 per diluted share. This is compared with reported revenues of $183.6 million and income from continuing operations of $5.0 million, or $0.15 per diluted share, for the same period in 2006. For the year ended December 31, 2007, Par reported total revenues of $769.7 million and income from continuing operations of $51.1 million, or $1.47 per diluted share. This is compared with reported revenues of $725.2 million and income from continuing operations of $6.7 million, or $0.19 per diluted share, for 2006.

Fourth quarter 2007 reported, or GAAP, income from continuing operations included a pre-tax gain of $3.1 million from the Company's sale of its remaining investment in Optimer Pharmaceutical, Inc. ("Optimer") common stock and $4.6 million of additional share-based compensation expense related to the Company's issued stock option tender offer. Adjusting for these items, income from continuing operations for the fourth quarter of 2007 was $6.5 million, or $0.19 per diluted share. By comparison, income from continuing operations for fourth quarter 2006 included a $3.2 million investment gain, tempered by severance costs of $5.2 million, and a $1.0 million asset impairment. Adjusting for these items, income from continuing operations for the fourth quarter of 2006 was $6.9 million, or $0.20 per diluted share.

Par's reported, or GAAP, income from cont
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008
2. China Sky One Medical, Inc. to Acquire Heilongjiang Tianlong Pharmaceutical, Inc.
3. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
4. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
5. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
6. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
7. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
8. Lotus Pharmaceuticals Raises $5 Million in Private Placement
9. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
10. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...sition in 2009 Continues Growth Trend , , NORTH...-- IPC The Hospitalist Company, Inc. (Nasdaq: IP...up practice company, announced today that it has a...Care Consultants, Inc. (MACC) in St. Louis, Missou... in the St. Louis market, where IPC has establishe...
(Date:1/8/2009)...8 A new educational Web...nce on drugs, biological products and medical devi...ality,s Centers for Education and Research on Ther... more than a dozen leading research centers nation...rmation Network ( CHAIN ) http://www.chainonline....
(Date:1/8/2009)...ption business continues to drive overall performa...- Zix Corporation (ZixCorp(R)), (Nasdaq: ZIXI ),...n and e-prescribing, today offered a corporate upd... , "We ended the year on a high note in our Emai...ders for the year in the fourth quarter," said Spu...
(Date:1/8/2009)...an. 8 St. Jude Children,s Research...ed that FedExCup Runner-Up,Camilo Villegas has in... a,pledge to match Singh,s donation of $5,000 to ... TOUR. Eagles for St. Jude is a powerful program ... Singh and rising LPGA star Morgan,Pressel, along...
Breaking Medicine News(10 mins):Health News:IPC The Hospitalist Company Acquires Missouri Practice Group 2Health News:AHRQ Announces New Web Site on Emerging Issues in Medical Therapeutics 2Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 2Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 3Health News:Zix Corporation CEO Provides Corporate Update for Q4 and Year-End 2008 4Health News:Not to be Outdone by FedExCup Champion Vijay Singh, FedExCup Runner-Up Camilo Villegas Increases Commitment to Children of St. Jude 2Health News:Not to be Outdone by FedExCup Champion Vijay Singh, FedExCup Runner-Up Camilo Villegas Increases Commitment to Children of St. Jude 3Health News:Not to be Outdone by FedExCup Champion Vijay Singh, FedExCup Runner-Up Camilo Villegas Increases Commitment to Children of St. Jude 4
...rly heart attack victims by quickly giving blood t...U.S. study found. Researchers said this advice, if...ch year. Taking care of anemia is probably as impo...ssolving drugs, which are already standard care fo...
... to intellectual impairment over the age of 64, re...chiatry in London carried out a community survey o...ople aged 65 and over. Smoking and drinking habits...he study. The volunteers' intellectual powers were...
...iness. Crew members have to spend days together in...they cannot call a doctor. The crew's bodies... major flight. This means they must get proper res...ble - no easy task given the nature of their chall...
...y, does good, scientists have claimed. Couples wh...an 10 years younger than the average adult who mak...logist Dr David Weeks, who has made a 10-year stud... from sex is a crucial factor in preserving youth....
Other Medicine News:Health News:Health at heights 2
(Date:1/7/2009)...opment Based On Osteotech,s Proprietary Human Coll...on; FDA Filing Anticipated in Third Quarter 2009 ...ll/ -- Osteotech, Inc. (Nasdaq: OSTE ), a lead...regenerative healing, announced today that it has ...h(TM) BioRegeneration Matrix. The first five patie...
(Date:1/7/2009)...Newswire/ -- Circassia Ltd, a specialty,biopharma...are, today,announced that following successful cl...ne(R) anti-allergy technology, the company has now...e II clinical trial in cat allergy. The,study, wh...nts with confirmed,cat allergies, and all the par...
(Date:1/6/2009)...intaining a healthy immune system , , PURCHASE,... study in Nutrition and Cancer (60(5), 643-651) ...ka, Japan has shown that AHCC (Active Hexose Corre...sing the number of dendritic cells (DCs). DCs are ...esenting foreign substances to other immune system...
(Date:1/6/2009)...swire/ -- The Michael J. Fox Foundation awarded a ...rch teams for pre-clinical research on potential n...funding was awarded under the Foundation,s Therap...t launched in 2006, supports and bolsters industry... part of MJFF,s focus on ,de-risking, preclinica...
Breaking Medicine Technology:Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 2Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment 3Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 2Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells 3Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinson's Disease Research 2National Federation of the Blind to Award 24100 000 7690 1National Federation of the Blind to Award 24100 000 7690 2ASH Honors Two Congressmen and NIDDK Director for their Public Service and Leadership in Hematology 7687 1ASH Honors Two Congressmen and NIDDK Director for their Public Service and Leadership in Hematology 7687 2Facial Deformity Danger 3F 7684 1Facial Deformity Danger 3F 7684 2Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting 2083 1Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting 2083 2Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting 2083 3Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting 2083 4Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting 2083 5Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting 2083 6Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting 2083 7Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting 2083 8
... - EPIX,Pharmaceuticals, Inc. (NASDAQ: EPIX) today...-00023, a novel long-acting 5-HT1A agonist,was fe... New,Clinical Drug Evaluation Unit (NCDEU) Meeting...by the National Institutes of,Health and the Ameri...resentation highlighted data from a randomized,do...
...d symptoms of SLE,disease at 52 Weeks and demonstr...6 weeks-, ROCKVILLE, Md., June 14, 2007 /PRNewswir...announced the presentation of Phase 2,trial data d...ificantly reduced disease activity across multiple...d quality of life in,patients with active systemic...
Other Medicine Technology:EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8
...r N395 Pulse Oximeter with Oxismart XL Advanced Si...onditions, cutting through nonspecific noise to fi...values. , ,The N395 monitor is also equipped ...n clinician-programmable alarm sensitivity for pul...
The Model 5305 is a hand-held, portable, lightweight pulse oximeter designed for spot checking. It has a NiCad rechargeable battery.
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery.
After inserting a finger into comfortable holder, measuring switch is automatically turned on, and continuous measurement is performed., ,Large display of approx. 11mm character height. In darke
Medicine Products: